乌帕替尼治疗急性重度溃疡性结肠炎的有效性和安全性分析
Efficacy and safety analysis of upadacitinib in the treatment of patients with acute severe ulcerative colitis
摘要
目的:评估乌帕替尼在急性重度溃疡性结肠炎(ASUC)患者一线及挽救治疗中的临床疗效和安全性。方法:采用回顾性队列研究方法。纳入2023年7月至2026年1月在空军军医大学西京医院消化内科接受乌帕替尼治疗的ASUC患者,将其分为一线治疗组与挽救治疗组(包含二线、三线治疗)。主要研究终点为90 d结肠切除率与第1周临床应答率;次要研究终点为治疗第0~7天每日Lichtiger评分,治疗第8周临床应答率、临床缓解率、内镜应答率、内镜缓解率,以及随访不良反应发生率。结果:共纳入22例ASUC患者,其中男11例,女11例;年龄36.0(33.3,46.8)岁;中位病程3.0(1.0,5.1)年;9例接受乌帕替尼一线治疗,6例接受二线治疗,7例接受三线治疗。一线、二线及三线治疗组患者90 d结肠切除率呈升高趋势,依次为11.1%(1/9)、33.3%(2/6)和57.1%(4/7),而第1周临床应答率呈逐步下降趋势,依次为77.8%(7/9)、66.7%(4/6)和42.9%(3/7)。所有组别第0~7天的Lichtiger评分均明显改善,其中一线治疗组评分下降更为迅速。3个治疗组第8周临床缓解率与内镜缓解率均呈下降趋势,依次为88.9%/88.9%(一线)、50.0%/33.3%(二线)、28.6%/14.3%(三线)。中位随访时间105.0(67.0,226.0)d,不良事件发生率为13.6%(3/22),均较轻微。结论:乌帕替尼在ASUC患者治疗中展现出较好的临床疗效和安全性。
Objective:To evaluate the efficacy and safety of upadacitinib as first-line and rescue therapies in patients with acute severe ulcerative colitis(ASUC).Methods:A retrospective cohort study was conducted. ASUC patients who received upadacitinib at the Department of Gastroenterology,Xijing Hospital,Air Force Medical University,from July 2023 to January 2026 were enrolled. Patients were categorized into first-line therapy group and rescue therapy group(including second-line and third-line therapies). The primary outcomes were the 90-day colectomy rate and clinical response rate at week 1. Secondary outcomes included daily Lichtiger scores from day 0 to day 7,clinical response and remission rates at week 8,endoscopic response and remission rates at week 8,and the rate of adverse events after follow-up period.Results:A total of 22 ASUC patients(11 males and 11 females)were enrolled,with a median age of 36.0(33.3,46.8)years and a median disease duration of 3.0(1.0,5.1)years. Nine patients received upadacitinib as first-line therapy,6 as second-line therapy,and 7 as third-line therapy. The 90-day colectomy rates in the first-line therapy,second-line therapy,and third-line therapy groups showed an increasing trend,being 11.1%(1/9),33.3%(2/6),and 57.1%(4/7),respectively. While,the clinical response rates at week 1 showed a progressively decreasing trend,being 77.8%(7/9),66.7%(4/6),and 42.9%(3/7),respectively. The Lichtiger scores from day 0 to day 7 improved in all groups,with a more rapid decline observed in the first-line therapy. The clinical and endoscopic remission rates at week 8 also showed a decreasing trend,being 88.9%/88.9%(first-line),50.0%/33.3%(second-line),and 28.6%/14.3%(third-line),respectively. The median follow-up duration was 105.0(67.0,226.0)days. The incidence of adverse events was 13.6%(3/22),and all adverse events were mild in severity.Conclusion:Upadacitinib has demonstrated good clinical efficacy and a favorable safety profile in the treatment of patients with ASUC.
年,卷(期):
2026, 10(5)
在线出版日期:
2026年9月25日